Arrowhead Pharmaceuticals (ARWR) Operating Expenses (2010 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 17 years of Operating Expenses data on file, last reported at $215.0 million in Q1 2026.

• Quarterly Operating Expenses rose 33.12% year-over-year to $215.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $843.9 million (up 27.14% YoY) and the FY2025 annual result came in at $731.1 million, up 20.92% from the prior year.
• Operating Expenses fell to $215.0 million in Q1 2026, from $223.2 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $223.2 million in Q4 2025 to a low of $98.1 million in Q1 2023.
• A 5-year average of $150.0 million and a median of $140.1 million in 2023 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses soared 80.61% — and 2023, when it slipped 11.02%.
• Tracing ARWR's Operating Expenses over 5 years: stood at $104.7 million in 2022, then soared by 33.83% to $140.1 million in 2023, then rose by 17.0% to $163.9 million in 2024, then jumped by 36.19% to $223.2 million in 2025, then decreased by 3.69% to $215.0 million in 2026.
• The last three Operating Expenses figures came in at $215.0 million (Q1 2026), $223.2 million (Q4 2025), and $212.4 million (Q3 2025), per Business Quant data.